Product Description
EvolveImmune is developing EV-105 as a treatment for b-cell malignancies. It is a best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation.(Sourced from: https://evolveimmune.com/our-pipeline/)
Mechanisms of Action: CD20 Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EvolveImmune
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|